To elucidate the role of the Src family kinase Lyn in B cell receptor (BCR) signaling, we and others previously generated lyn -/-mice and analyzed their B cell responses. Although the initiation of BCR signaling in lyn -/-B cells is delayed, BCR-induced ERK2 activation and proliferation are enhanced. As the co-receptors FcγRIIb1 and CD22 have been shown to be negative regulators of BCR signaling, we have now examined their functional roles in lyn -/-B cells.
Background
B cell receptor (BCR) engagement leads to the activation of the tyrosine kinases Syk and Btk and of Src family tyrosine protein kinases. This activation results in increases in the following cellular events: tyrosine phosphorylation of numerous signaling proteins; phosphatidylinositol turnover; the elevation of intracellular free calcium; and the activation of serine/threonine kinase cascades such as the extracellular signal-regulated kinase (ERK), Jun Nterminal kinase (JNK) and p38 pathways [1] . The signaling events triggered by the BCR can be modulated by co-receptors such as CD19, FcγRIIb1 and CD22, which associate with the BCR either constitutively or in a liganddependent manner [2] . These factors contribute to determining whether B lymphocytes respond positively to antigen-induced BCR signaling by proliferating or negatively by undergoing anergy or apoptosis.
Co-ligation of FcγRIIb1 with the BCR, which occurs when antigen is presented in the form of immune complexes with immunoglobulin (Ig) G, results in the dephosphorylation of CD19 and in decreases in a range of cellular processes: phosphatidylinositol turnover; transmembrane calcium influx; signaling through the Ras pathway; and B cell proliferation [3] [4] [5] [6] . The inhibitory effects of FcγRIIb1 are dependent on a tyrosine motif in its cytoplasmic domain which is phosphorylated upon co-ligation with the BCR [7] . Both the inositol phosphatase SHIP and the tyrosine phosphatase SHP-1 are recruited by FcγRIIb1 [8, 9] , but the inhibitory effects of FcγRIIb1 appear to be primarily mediated by SHIP [10, 11] .
CD22 is another membrane protein that regulates BCR signaling and is associated with the BCR at low stoichiometry, becoming tyrosine phosphorylated and binding to SHP-1 upon BCR engagement [12] [13] [14] [15] [16] [17] . Calcium signaling appears to be one of the BCR signaling pathways that is negatively regulated by CD22, as B cells from mice lacking CD22 have exaggerated calcium responses to BCR signaling [18] [19] [20] [21] . Other signaling events regulated by CD22 include the activation of mitogen-activated protein (MAP) kinase pathways, which are suppressed when CD22 is co-ligated with the BCR signaling complex and are enhanced when CD22 is ligated alone before BCR engagement [22] . In addition, CD22 alone seems to mediate a positive signal in B cells [14, 23] .
We and others have previously shown that B cells from lyn -/-mice exhibit a hyperproliferative response to BCR signaling [24, 25] , which correlates with an enhanced activation of the Ras/ERK pathway [25] and evidence of autoimmunity in these mice in vivo [25] [26] [27] . Here, we demonstrate that lyn -/-B cells also have enhanced JNK activation, as well as an increased calcium response to BCR signaling compared with wild-type B cells. These results suggest that one or more downregulatory signaling pathways are dependent on Lyn. In the absence of Lyn, the tyrosine phosphorylation of FcγRIIb1 induced by intact anti-IgM antibody was reduced, and the tyrosine phosphorylation of CD22 was almost completely absent. We examined the inhibitory functions of FcγRIIb1 and CD22 in the absence of Lyn and found that the ability of CD22 to mediate inhibition of BCR-induced calcium signaling was dramatically impaired.
Results

Enhanced activation of the ERK and JNK pathways in lyn -/-B cells
We previously found that ERK1, ERK2 and the MAP kinase kinase MEK1 were hyperactivated at all time points examined after BCR engagement in lyn -/-B cells [25] . To examine whether the BCR-induced activation of other serine/threonine kinase pathways was also altered, we assayed for JNK activity by an in vitro kinase assay (Figure 1a) . The activation of JNK at intermediate doses of anti-IgM antibody was higher in lyn -/-B cells than in wild-type B cells; this effect was also observed for ERK2 activation (Figure 1b ; [25] ). BCR cross-linking only weakly activated p38 kinase and there was no significant difference between wild-type and lyn -/-B cells (data not shown). One BCR-induced early response gene that is dependent on the Ras/ERK pathway is egr-1 [28] . BCR-induced Egr-1 protein expression was enhanced in lyn -/-B cells (Figure 1c) , indicating that the enhanced activation of the Ras/ERK pathway affected downstream gene induction.
Exaggerated calcium signaling in lyn -/-B cells
The hyperproliferative phenotype and the hyperactivation of the ERK and JNK pathways in lyn -/-B cells suggested that Lyn is important for the mechanisms that negatively modulate these pathways. B cells from mice that are deficient for proteins involved in BCR signal downregulation, such as FcγRIIb1, CD22 and SHP-1, all have exaggerated calcium signaling [18] [19] [20] [21] 29, 30] . We therefore examined the calcium responses in lyn -/-B cells. A higher elevation of intracellular calcium in lyn -/-B cells than in wild-type B cells was observed in response to BCR cross-linking both in the absence of FcγRIIb1 inhibition, using anti-IgM F(ab′) 2 antibody fragments for stimulation (Figure 2a,b) , and in the presence of FcγRIIb1 inhibition, using intact rabbit antiIgM antibodies (Figure 2c Figure 2f ). This suggested that the higher sustained calcium levels observed in lyn -/-B cells were primarily due to transmembrane calcium influx (Figure 2e ).
The data in Figure 2e ,f also show a slightly longer delay before the initiation of the calcium response in the lyn -/-B cells. A delay in calcium response was consistently observed in lyn -/-B cells over a wide range of anti-IgM antibody doses (compare Figure 2a with 2b) . We have previously reported that BCR-induced tyrosine phosphorylation of a number of substrates was also delayed in lyn -/-B cells [25] . These results are consistent with the model that Lyn participates in the initiation of the BCR signal in addition to signal downregulation.
Normal surface expression of FcgRIIb1 and CD22 in lyn -/-B cells
One possible explanation for defective downregulation of the BCR signal would be decreased expression of inhibitory molecules in lyn -/-B cells, such as FcγRIIb1 and CD22. The level of cell surface expression of these two proteins was examined by flow cytometry and was found to be identical in wild-type and lyn -/-B cells (data not shown).
Decreased tyrosine phosphorylation of FcgRIIb1 and CD22
To investigate the biochemical basis for the defective negative regulation in lyn -/-B cells, we examined the tyrosine phosphorylation of FcγRIIb1 and CD22 after BCR engagement. As shown in Figure 
Blocking FcgRIIb1 enhances the BCR-induced calcium response in both wild-type and lyn -/-B cells
Given the reduction of the BCR-induced tyrosine phosphorylation of FcγRIIb1 and CD22, it was of interest to investigate whether the inhibitory functions of these proteins were impaired. We pretreated cells with an antibody (2.4G2) that binds to FcγRII and prevents it from being co-ligated with the BCR and examined the calcium response to intact rabbit anti-IgM antibody. Pretreatment with 2.4G2 augmented the calcium response in both wildtype and lyn -/-B cells (Figure 4a,b) . This is consistent with our previous observation that 2.4G2 pretreatment enhances proliferation and ERK2 activation by intact rabbit anti-IgM antibody in lyn -/-B cells [25] and suggests that FcγRIIb1-mediated inhibition of these events is at least partially functional in the absence of Lyn.
Preligating CD22 enhances the BCR-induced calcium response in wild-type but not in lyn -/-B cells B cells from CD22 -/-mice have an increased calcium response upon BCR stimulation, suggesting that CD22 participates in the downregulation of this calcium response [18] [19] [20] [21] . Given the dramatic reduction in phosphorylation of CD22 in lyn -/-B cells, we examined whether CD22 function was affected, using an approach analogous to the FcγRIIb1 pre-blocking experiment described in Figure 4a ,b above. Anti-IgM F(ab′) 2 antibody fragments were used for stimulation in this and the following series of experiments to avoid the involvement of FcγRIIb1. Preligation of CD22 enhanced the BCRinduced calcium response in wild-type B cells (Figure 4c,e) . When a secondary antibody was used to further cross-link ('super-crosslink') the anti-CD22 antibody before anti-IgM antibody stimulation, the resulting calcium response was further increased. As the preligation of CD22 and the lack of CD22 expression both resulted in enhanced calcium responses, a probable interpretation of this result is that preligation of CD22 sequesters this co-receptor away from the BCR signaling complex and thereby prevents its inhibition of the BCRinduced calcium response. In contrast to its effect in wildtype B cells, CD22 preligation did not result in a comparable enhancement of anti-IgM induced calcium flux in lyn -/-B cells (Figure 4d ,f).
The lack of calcium signal enhancement by anti-CD22 antibody pretreatment in lyn -/-B cells was not due to these cells having already attained a maximal level of signaling, as these experiments were carried out at intermediate doses of anti-IgM F(ab′) 2 antibody fragments for wild-type and lyn -/-B cells as determined in Figure 2 . Note that it is possible for lyn -/-B cells to achieve calcium responses higher than that observed in Figure 4f at higher doses of anti-IgM antibody (Figures 4d,2b) . Indeed, the lyn -/-B cells had a defect in CD22 regulation of the BCRinduced calcium response over a wide range of doses of anti-IgM antibody (data not shown). Analogous experiments were performed with another anti-CD22 antibody (CY34.1) and results similar to those in Figure 4c -f were obtained (data not shown). These experiments indicated that the ability of CD22 to regulate calcium signaling in a negative manner was impaired in the absence of Lyn.
CD22 regulation of ERK2 and JNK pathways
We next examined the effects of CD22 preligation on the ERK and JNK pathways. Wild-type B cells that were 
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Current Biology treated with anti-CD22 antibodies followed by supercrosslinking using a secondary antibody had enhanced activation of ERK2 (Figure 5a ) and JNK1/2 (Figure 5b ) by anti-IgM antibody. These results are similar to those of previously reported experiments using biotinylated anti-CD22 F(ab) fragments followed by avidin treatment [22] . Despite the already elevated activities of these kinases in lyn -/-B cells compared with wild-type B cells following stimulation with anti-IgM antibody, anti-CD22 pretreatment and super-crosslinking further enhanced the ERK2 and JNK responses in lyn -/-B cells. In all the experiments that we have performed, CD22 pretreatment consistently led to an increase in ERK2 and JNK1/2 activities in both wild-type and lyn -/-B cells (Table 1) . In each experiment, the fold increase in activities of these kinases after CD22 pretreatment was lower in lyn -/-B cells than in wild-type B cells. It is possible that the ability of CD22 to negatively regulate the ERK2 and JNK1/2 pathways was somewhat diminished in the absence of Lyn. Alternatively, the difference in enhancement may simply reflect the fact that BCR stimulation of lyn -/-B cells by itself caused a greater activation of ERK2 and JNK1/2, resulting in a reduced ability to increase this activation. Nevertheless, it is clear that although the absence of Lyn caused a striking impairment of CD22 function in the downregulation of the calcium response, some CD22-mediated downregulation of ERK2 and JNK pathways was still evident.
Discussion
Of the Src family tyrosine kinases, Lyn is the most highly expressed in B cells. These kinases have historically been regarded as signal initiators in BCR signaling, on the basis of their association with the BCR upon activation [32] , their kinetics of activation [33] , and the presence of tyrosine-containing sequences in the cytoplasmic domains of Igα and Igβ that resemble motifs for phosphorylation by Src family kinases [34, 35] . Consistent with a signal-initiating role for Lyn in BCR signaling, lyn -/-B cells have decreased or delayed tyrosine phosphorylations of specific substrates involved in BCR signaling [25, 27, 36] , as well as a slight delay in the initiation of their calcium responses to anti-IgM antibody, as shown in this study (Figure 2) . Surprisingly, the major phenotype of lyn -/-B cells was found to be dramatic hyperproliferative responses and enhanced MEK1/ERK activation upon anti-IgM antibody treatment, suggesting that Lyn has a unique role among Src family kinases in downregulating B cell responses to antigenic stimulation [24, 25] . Here, we extended these studies and found that the BCR-induced activation of JNK1/2 and transmembrane calcium influx were also enhanced in lyn -/-B cells.
In order to understand the molecular basis of the defective downregulation of BCR signaling in lyn -/-B cells, we first examined the FcγRIIb1 pathway. Blocking FcγRIIb1 using the 2.4G2 antibody enhanced the proliferation [25] . However, the 2.4G2 antibody was able to enhance the calcium response (Figure 4b ), ERK2 activation and proliferative response [25] of lyn -/-B cells to intact rabbit anti-IgM antibody, which binds more strongly to FcγRIIb1 than does goat anti-IgM antibody. It therefore appears that FcγRIIb1 is at least partially functional in the absence of Lyn, which corresponds to a partial impairment of FcγRIIb1 tyrosine phosphorylation in lyn -/-B cells upon co-ligation with the BCR by intact rabbit anti-IgM antibody. A probable explanation is that the phosphorylation of FcγRIIb1 can be carried out by kinases other than Lyn, although less efficiently.
In contrast to FcγRIIb1 phosphorylation, we observed a drastic reduction of CD22 phosphorylation in lyn -/-B cells, suggesting that Lyn is uniquely required for most of the basal and BCR-induced phosphorylation of CD22. The cytoplasmic domain of murine CD22 contains six tyrosine residues, four of which are predicted to be good substrates for Src family kinases [34, 35] due to the presence of a leucine or isoleucine residue at the +3 position (numbering onwards from the tyrosine residue) [37] . The basal and BCR-induced phosphorylation of CD22 was normal in B cells lacking the expression of Fyn, another Src family kinase expressed in B cells (data not shown). Perhaps the unique requirement for Lyn to phosphorylate CD22 efficiently relates to the association between Lyn and the cytoplasmic region of CD22 [14] .
The reduction in CD22 phosphorylation in lyn -/-B cells correlates with an impairment of CD22-mediated negative regulation of the BCR-induced calcium elevation. Whereas in wild-type B cells, cross-linking of CD22 (probably causing its sequestration from the BCR) enhanced BCR-induced calcium elevation, this treatment did not affect calcium elevation in lyn -/-B cells (Figure 4c-f) . This result suggests that Lyn is responsible for the phosphorylation of one or more tyrosine residues in CD22 that is/are critical for its ability to regulate the calcium pathway in a negative manner. Whilst this manuscript was under review, Smith et al. [38] also reported enhanced calcium responses and decreased CD22 phosphorylation in response to BCR stimulation of lyn -/-B cells. The enhanced calcium responses in lyn -/-B cells were dependent on the presence of extracellular calcium ( Figure 2f ) and a similar observation was also made in CD22 -/-B cells [21, 39] . It is interesting to note that in addition to the exaggerated calcium response in B cells, lyn -/-and CD22 -/-mice both have an increased rate of B cell turnover, reduced numbers of HSA lo B220 hi B cells and elevated levels of serum Ig (Figure 2 ; [18] [19] [20] [21] [25] [26] [27] ). Taken together, these results suggest that the negative effects of Lyn on BCR-induced calcium elevation are likely to be mediated by the tyrosine phosphorylation of CD22 and engagement of the inhibitory functions of CD22.
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Figure 5
Preligation of CD22 enhances BCR-induced activation of ERK2 and JNK pathways in both wild-type and lyn -/-B cells. Purified splenic B cells were incubated with media alone or with rat anti-CD22 antibody (2D6) at 15 µg per 10 7 cells in 1 ml media at room temperature for 30 min. Cells were washed and equilibrated at 37°C for 10 min. Goat F(ab′) 2 fragments against rat IgG (2°) were subsequently added to the indicated samples and incubated at 37°C for 3 min before stimulation with goat F(ab′) 2 fragments against mouse IgM for 10 min. (a) ERK2 and (b) JNK1/2 were immunoprecipitated by specific antibodies and their activities assayed by in vitro kinase assays using GST-Elk-1 and GST-c-Jun as substrates respectively. The kinase reactions were resolved by SDS-PAGE and transferred to nitrocellulose. The levels of 32 P incorporation were quantitated using a PhosphorImager and represented as relative activity with respect to the unstimulated wild-type sample. The nitrocellulose filters were also immunoblotted for the respective kinases to verify equivalent loading. ERK2* represents the active form of ERK2. Note that the relative ERK2 activity in the last lane is atypically high in this experiment and was around the same level as stimulation with anti-IgM antibody alone in other experiments.
Anti-CD22 2º antibody F(ab') 2 anti-IgM One surprising result from these studies is that despite the dramatic reduction of tyrosine phosphorylation on CD22 in lyn -/-B cells, some negative regulation of the ERK2 and JNK pathways by CD22 was still evident in lyn -/-B cells. As CD22 phosphorylation did increase slightly upon stimulation of lyn -/-B cells with anti-IgM antibodies, it is possible that those sites phosphorylated independently of Lyn are sufficient to mediate at least partial negative regulation of the ERK2 and JNK pathways. Alternatively, it is also possible that the ability of CD22 to regulate these kinase pathways does not rely upon tyrosine phosphorylation of CD22. Some anti-CD22 monoclonal antibodies have been shown to induce or enhance B cell proliferation [23, 40] and those results were interpreted as a positive signal being sent by cross-linked CD22. It should be noted, however, that the rat anti-CD22 antibody used to cross-link CD22 in our experiments induced negligible proliferation of wild-type or lyn -/-B cells, even with the addition of secondary cross-linking antibodies (data not shown). Thus, the enhanced responses that we observed with this anti-CD22 antibody more likely reflect the sequestration of CD22 and prevention of its inhibitory function, rather than the generation of positive signals triggered by cross-linking of CD22. Nonetheless, it is clear that the ability of CD22 to regulate BCR-induced calcium elevation and BCR-induced activation of ERK2 and JNK are mechanistically distinct, as only the former is critically dependent on Lyn.
It is interesting to note that the levels of ERK2 and JNK activation ( Figure 5 , Table 1 ), as well as those of calcium mobilization (Figure 4) , induced by anti-IgM F(ab′) 2 antibody fragments in anti-CD22-pretreated lyn -/-B cells were still higher than the levels induced in similarly treated wild-type B cells. This could reflect an incomplete ability of anti-CD22 antibodies to remove the inhibitory effect of CD22. Another possibility is that negative regulatory mechanisms, other than those involving FcγRIIb1 and CD22, may also be defective in the absence of Lyn.
Conclusions
The hyperproliferative response to BCR signaling in lyn -/-B cells correlates with hyperactivation of the ERK2 and JNK pathways and elevated calcium responses, suggesting an inhibitory role for Lyn in BCR signaling. One of the mechanisms by which Lyn downregulates the BCR signal is probably mediated by its phosphorylation of CD22. Our data indicate that Lyn is required for CD22 to inhibit the BCR-induced calcium response, but not for it to inhibit the induced activation of ERK and JNK. In contrast, many of the FcγRIIb1-mediated inhibitory functions appear to be at least partially functional in lyn -/-B cells. Functional defects in the ability of CD22, and possibly other regulatory pathways, to inhibit BCR signaling contribute to the hyperresponsiveness of lyn -/-B cells and may be the underlying reason for the development of autoimmunity observed in lyn -/-mice.
Materials and methods
Cells
All experiments were carried out with cells isolated from 6-11-weekold mice. All the mice used had no evidence of splenomegaly. Purified splenic B lymphocytes were prepared as previously described [25] .
Antibodies and other reagents
Rabbit antiserum against GST-CD22 used for CD22 immunoblotting was a generous gift from Mary-Ann Campbell [16] . Affinity-purified anti-Lyn antibody [41] and anti-Syk antiserum [42] were described previously. Except where noted otherwise, the anti-CD22 antibody used in the CD22 pretreatment experiments was the rat monoclonal anti-CD22 antibody, 2D6, from Southern Biotechnology. Goat F(ab′) 2 fragments against mouse IgM (Fc-specific), intact rabbit anti-mouse IgM, goat F(ab′) 2 fragments against rat IgG (Fc-specific) and goat F(ab′) 2 fragments against mouse IgG (Fc-specific) were obtained from Jackson Immunological Research. The latter two reagents were used as secondary cross-linking antibodies for the rat anti-CD22 antibody 2D6 and mouse anti-CD22 antibody CY34.1, respectively. Cultured supernatants were generated from hybridomas (2.4G2, anti-FcγRII; CY34.1, anti-CD22) obtained from ATCC. Rabbit polyclonal anti-ERK2 (C-14), anti-JNK1 and anti-JNK2 were obtained from Santa Cruz Biotechnology. FITC-conjugated anti-mouse IgG1, FITC-conjugated anti-rat IgG2b, PE-conjugated RA3-6B2 (anti-B220), PE-conjugated Research Paper Lyn in negative regulation of BCR signaling Chan et al. 551 Table 1 Summary of ERK2 and JNK1/2 activation. Five independent experiments were carried out as described in the legend to Figure 5 . In experiments 1 and 2, the CY34.1 mouse monoclonal anti-CD22 antibody was used, whereas in experiments 3-5, the 2D6 rat monoclonal anti-CD22 antibody was used for anti-CD22 antibody pretreatment. In vitro kinase activities of ERK2 and JNK1/2 in wild-type and lyn -/-B cells were normalized within each experiment to the unstimulated wild-type sample and represented as relative activities.
anti-CD11b, PE-conjugated anti-CD4 and PE-conjugated anti-CD8 were obtained from Pharmingen. Propidium iodide was from Calbiochem. Except where indicated, cell culture medium used for B cell purification, incubation and stimulation was RPMI 1640 supplemented with 5% FCS (Gibco/BRL), 2 mM pyruvate, 2 mM glutamine and 50 µM 2-mercaptoethanol.
Flow cytometric analysis
Analysis was performed on a FACScan (Becton Dickinson) and the data acquired to a Macintosh 7300 running CellQuest v3.1 software.
Calcium analysis
Splenocytes (depleted of RBCs) were incubated at 10 7 per ml culture medium (see above) plus 10 mM HEPES with 3 µM Fluo-3 AM (Molecular Probes) at 37°C for 30 min. Cells were washed and stained with PE-conjugated anti-CD11b, anti-CD4 and anti-CD8 antibodies along with 1 µg/ml propidium iodide for 30 min at room temperature. In experiments involving pretreatment with 2.4G2 (anti-FcγRII) or rat anti-CD22 (Southern Biotechnology) antibodies, hybridoma supernatant or antibodies were added along with the PE-conjugated antibodies during the same incubation step. Cells were subsequently washed and resuspended at 5 × 10 6 per ml culture medium containing 10 mM HEPES at 37°C. To super-crosslink CD22, F(ab′) 2 anti-rat IgG was added to a final concentration of 10 µg/ml 3 min before anti-IgM antibody stimulations. Fluo-3 fluorescence of viable cells (based on propidium iodide exclusion) in the lymphocyte size gate (based on forward and side scattering properties) that were CD11b -CD4 -CD8 -was analyzed by flow cytometry. Results were plotted as the mean Fluo-3 fluorescence at 20 sec intervals. In each experiment, wild-type and lyn -/-cells were also stimulated with 2 µM calcium ionophore A23187 (Calbiochem) to verify equivalent Fluo-3 loading in both cell types. In experiments in which cells were stimulated in the presence of EGTA, EGTA was added to a final concentration of 1 mM immediately before flow cytometric analysis and cells were stimulated within 3 min of EGTA addition.
In vitro kinase assays ERK2 activity was assayed using GST-Elk-1 as a substrate as previously described [25] . The same buffer system and reaction conditions were used to assay for JNK except that GST-c-Jun(1-79) [43] was used as a substrate for JNK. Antibodies that recognize both JNK1 and JNK2 were used to immunoprecipitate JNK from lysates. The kinase reactions were resolved either on 10% low-bis gels (SDS-polyacrylamide gels containing an acrylamide:bis-acrylamide ratio of 120:1) for ERK2 or on 10% regular gels (acrylamide:bis-acrylamide ratio of 37.5:1) for JNK. The proteins in the resolving gels were transferred to nitrocellulose. After exposure to film and to PhosphorImager screens (Molecular Dynamics) for quantitation, the nitrocellulose membranes were immunoblotted for the respective kinases to verify equivalent loading.
Immunoprecipitations and immunoblotting
Preparation of cell lysates, protein quantitation, immunoprecipitations and immunoblotting were performed as previously described [25] . FcγRIIb1 was immunoprecipitated by 2.4G2 antibodies that were covalently coupled to protein-G-Sepharose beads using 20 mM dimethylpimelimidate (Pierce).
